The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide derivatives and to their use in therapy, particularly for the treatment of obesity or nicotine dependence.
UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS
申请人:[en]ANGELINI PHARMA S.P.A.
公开号:WO2024121048A1
公开(公告)日:2024-06-13
The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2/7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particularly in the treatment of disorders of the central nervous system (CNS), such as, for example, epilepsy and neurodegenerative disorders, and of the peripheral nervous system (PNS), such as, for example, chronic and neuropathic pain.
WO2006/100208
申请人:——
公开号:——
公开(公告)日:——
1-benzylindole-2-carboxamide derivatives
申请人:N.V. Organon
公开号:US07671080B2
公开(公告)日:2010-03-02
The present invention relates to i-benzylindole-2-carboxamide derivatives of formula I, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 1-benzylindole-2-carboxamide derivatives and to their use in therapy, particularly for the treatment of obesity or nicotine dependence.